Zai Lab gets priority review for lung cancer dug repotrectinib in China
Pixelimage/iStock via Getty Images
- China's National Medical Products Administration (NMPA) granted priority review to Zai Lab's (NASDAQ:ZLAB) repotrectinib to treat adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC).
- A priority status helps expedite the review and approval timelines.
- "The CDE’s decision to grant priority review to repotrectinib underscores repotrectinib as a potential next-generation best-in-class treatment for ROS1-positive NSCLC in both TKI-naïve and pretreated patients in China," said Rafael Amado, president, head of Global Oncology Research and Development at Zai.
- Repotrectinib, a tyrosine kinase inhibitor (TKI), is being evaluated by Bristol Myers Squibb (BMY) and Zai in a phase 1/2 trial called TRIDENT-1 in adults and a phase 1/2 study, dubbed, CARE in children.
- In April, Foundation Medicine said it expanded collaboration with Bristol Myers to develop a tissue-based test FoundationOne CDx, as a companion diagnostic for the oral cancer drug repotrectinib.
- Bristol-Myers Squibb: Attractive Entry As New Products Sales Accelerate
- Zai Lab Sees Profits On The Horizon As Commercialization Accelerates